Related references
Note: Only part of the references are listed.Dynamic immune profiling identifies the stronger graft-versus-leukemia (GVL) effects with haploidentical allografts compared to HLA-matched stem cell transplantation
Huidong Guo et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2021)
Comparison of Two Strategies for Prophylactic Donor Lymphocyte Infusion in Patients With Refractory/Relapsed Acute Leukemia
Qiongqiong Su et al.
FRONTIERS IN ONCOLOGY (2021)
Haploidentical transplantation might have superior graft-versus-leukemia effect than HLA-matched sibling transplantation for high-risk acute myeloid leukemia in first complete remission: a prospective multicentre cohort study
Sijian Yu et al.
LEUKEMIA (2020)
Haploidentical versus HLA-matched sibling transplantation for refractory acute leukemia undergoing sequential intensified conditioning followed by DLI: an analysis from two prospective data
Sijian Yu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Haploidentical donor is preferred over matched sibling donor for pre-transplantation MRD positive ALL: a phase 3 genetically randomized study
Ying-Jun Chang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Two dose levels of rabbit antithymocyte globulin as graft-versus-host disease prophylaxis in haploidentical stem cell transplantation: a multicenter randomized study
Ren Lin et al.
BMC MEDICINE (2019)
Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients
Yu Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Minimal residual disease status determined by multiparametric flow cytometry pretransplantation predicts the outcome of patients with ALL receiving unmanipulated haploidentical allografts
Xiao-Su Zhao et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Dalila Salvatore et al.
HAEMATOLOGICA (2018)
The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology
Lanping Xu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Dalila Salvatore et al.
HAEMATOLOGICA (2018)
The consensus on the monitoring, treatment, and prevention of leukemia relapse after allogeneic hematopoietic stem cell transplantation in China
Yu Wang et al.
CANCER LETTERS (2018)
Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis
Ying-Jun Chang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Practical recommendations for reporting Fine-Gray model analyses for competing risk data
Peter C. Austin et al.
STATISTICS IN MEDICINE (2017)
Haploidentical transplantation compared with matched sibling and unrelated donor transplantation for adults with standard-risk acute lymphoblastic leukaemia in first complete remission
Li-Jie Han et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease-Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stern Cell Transplantation in Patients with Refractory/Relapsed Acute Leukemia
Chen-Hua Yan et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1
Jurjen Versluis et al.
BLOOD ADVANCES (2017)
Haploidentical versus Matched-Sibling Transplant in Adults with Philadelphia-Negative High-Risk Acute Lymphoblastic Leukemia: A Biologically Phase III Randomized Study
Yu Wang et al.
CLINICAL CANCER RESEARCH (2016)
Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis
Nilanjan Ghosh et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?
Daisuke Araki et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?
Ying-Jun Chang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia
Y. Zhou et al.
LEUKEMIA (2016)
Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study
Yu Wang et al.
BLOOD (2015)
Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation
Shernan G. Holtan et al.
BLOOD (2015)
Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia
Nathalie Dhedin et al.
BLOOD (2015)
Lower dose anti-thymocyte globulin for GvHD prophylaxis results in improved survival after allogeneic stem cell transplantation
L. Binkert et al.
BONE MARROW TRANSPLANTATION (2015)
Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact on Outcome in Acute Myeloid Leukemia
Xueyan Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation
R. B. Walter et al.
LEUKEMIA (2015)
HLA-Haploidentical Donor Lymphocyte Infusions for Patients with Relapsed Hematologic Malignancies after Related HLA-Haploidentical Bone Marrow Transplantation
Amer M. Zeidan et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Antifungal Agents for Secondary Prophylaxis Based on Response to Initial Antifungal Therapy in Allogeneic Hematopoietic Stem Cell Transplant Recipients with Prior Pulmonary Aspergillosis
Qifa Liu et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Haploidentical transplantation: the search for the best donor
Rupert Handgretinger
BLOOD (2014)
Pilot Study of Prophylactic Ex Vivo Costimulated Donor Leukocyte Infusion After Reduced-Intensity Conditioned Allogeneic Stem Cell Transplantation
Anita J. Kumar et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
High Alloreactivity of Low-Dose Prophylactic Donor Lymphocyte Infusion in Patients with Acute Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation with an Alemtuzumab-Containing Conditioning Regimen
Maria Liga et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis
Vikas Gupta et al.
BLOOD (2013)
Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission
Roland B. Walter et al.
BLOOD (2013)
Allogeneic hematopoietic cell transplantation from alternative sources for adult Philadelphia chromosome-negative ALL: what should we choose when no HLA-matched related donor is available?
S. Nishiwaki et al.
BONE MARROW TRANSPLANTATION (2013)
T-Cell-Replete HLA-Haploidentical Hematopoietic Transplantation for Hematologic Malignancies Using Post-Transplantation Cyclophosphamide Results in Outcomes Equivalent to Those of Contemporaneous HLA-Matched Related and Unrelated Donor Transplantation
Asad Bashey et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation
Xiao-Su Zhao et al.
ANNALS OF HEMATOLOGY (2012)
Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation
Chen-Hua Yan et al.
BLOOD (2012)
Prevention of relapse using granulocyte CSF-primed PBPCs following HLA-mismatched/haploidentical, T-cell-replete hematopoietic SCT in patients with advanced-stage acute leukemia: a retrospective risk-factor analysis
Y. Wang et al.
BONE MARROW TRANSPLANTATION (2012)
Wilms' tumor gene 1 expression: an independent acute leukemia prognostic indicator following allogeneic hematopoietic SCT
X-S Zhao et al.
BONE MARROW TRANSPLANTATION (2012)
Acute Lymphoblastic Leukemia
Joseph C. Alvarnas et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2012)
Modified donor lymphocyte infusion (DLI) for the prophylaxis of leukemia relapse after hematopoietic stem cell transplantation in patients with advanced leukemia - Feasibility and safety study
Xiao-Jun Huang et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2008)
Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation
Xiao-Jun Huang et al.
HAEMATOLOGICA (2007)
Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia - A metaanalysis
Masamitsu Yanada et al.
CANCER (2006)
Share Paper
